IPO investors pay up for Freeline as biotech fever rises

Sam Kerr

August 07, 2020 11:15 AM

NY_financial_district_Adobe_575x375. — famous New York Financial District with american flags in front of the Stock Exchange Building in the early morning sun, Manhattan financial district | Felix Pergande/Felix Pergande - stock.adobe.com

Freeline, the UK gene therapeutics company, has priced its IPO on the Nasdaq exchange at the top of the pricing range, with investors willing to pay a big premium for the stock. The company is the latest deal in a global biotech issuance spree that has passed $60bn.

Unlock this article.

The content you are trying to view is exclusive to our subscribers.

To unlock this article:

Request a Free Trial or Login

Topics

Equity IPOs Equity United States Americas North America

SK

Sam Kerr